Flush with a new, multibillion-dollar drug franchise, a booming Gilead is now hiring investigators for its fast-growing operations in Canada. The biotech is doubling down on its $100 million R&D investment in Alberta, Canada, with plans to expand on the new lab that opened this week at its Edmonton campus as it hires up to 170 more scientists for its R&D work.
Gilead Sciences said it's investing an additional $100 million to expand its operations in Edmonton, Canada.
GlobeImmune's in-development vaccine for hepatitis B missed the mark in a Phase II trial, marring the value of a program licensed to Gilead Sciences.
Gilead Sciences has a new swath of research showing that investing in new hep C therapies could potentially save the U.S. and Europe billions of dollars in lost productivity.
Federal authorities have rounded up nearly three dozen people indicted in a far-ranging scheme in which they allegedly sold $200 million worth of diverted drugs that included blockbusters like Bristol-Myers Squibb's antipsychotic Abilify, Gilead Sciences' HIV med Truvada and Novartis' cancer drug Gleevec.
A new generation of hep C therapies could offer key safety advantages over older treatments, as a recent analysis by healthcare informatics firm AdverseEvents found that Gilead Sciences' Sovaldi and Harvoni were linked to fewer serious side effects in postmarketing data.
As market watchers wonder whether Gilead Sciences is on the verge of a blockbuster buyout, the Big Biotech inked a small deal that will beef up its efforts in the growing field of epigenetics.
Generic drug companies Dr Reddy's Laboratories and Natco Pharma gained more than 2% on Monday as Mylan said its Indian unit will start sales of Gilead Sciences' Sovaldi (sofosbuvir 400) in India, a move that diminishes the likelihood of compulsory licensing of the drug as generic copies have already been licensed to local companies.
Gilead Sciences brushed aside any concerns about the effects of discounting of superseller hepatitis C drugs Sovaldi and Harvoni by blasting past analysts' earnings estimates of how much the drugs would sell, total revenues, earnings per share, and just about any other measure the markets could dig up. And flush with cash, Gilead execs say, it just may be time to go out and buy some stuff.
On pace to reap $29 billion in revenue this year thanks to its surging hepatitis C franchise, Gilead Sciences has the cash to pull off a big deal or two, and management is eyeing a slew of late-stage opportunities.